ArticleFrontiers in cardiovascular medicine2026
Evolution of advanced revascularization strategies for high-risk pulmonary embolism: a physiology-guided single-center experience.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of pulmonary embolism (PE) has evolved substantially over the past several decades, yet optimal integration of emerging therapies remains challenging. This Perspective describes our 4 decade, single-center experience reflecting the transition from systemic thrombolysis to catheter-directed therapies (CDT) and, more recently, large bore mechanical thrombectomy supported by interventional cardiology with ECMO back-up. Our approach has increasingly focused on physiologic assessment including right ventricular function, pulmonary artery pressures, and cardiac output in the face of the patient's age, underlying cardiopulmonary disease and presence of proximal deep vein thrombosis. This evolution has been characterized by progressive adoption of CDT, reassessment, and refinement of therapies in response to both clinical experience, emerging evidence and participation in clinical trials. The development of a pulmonary embolism response team (PERT) and more recently integration of artificial intelligence detection systems have further improved early recognition of intermediate and high-risk PE cases and coordination of care. Our experience over four decades highlights key lessons and the importance of early physiologic recognition of severity, selective use of reperfusion therapies, and the critical role of a dedicated multidisciplinary system of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.